Földes K, Makláry E, Vargha P, Janssen J, Járay J, Perner F, Geró L
Transplantation and Surgical Clinic, Semmelweis University, Budapest, Hungary.
Transpl Int. 1998;11 Suppl 1:S65-8. doi: 10.1007/s001470050428.
The effect of a cholesterol-lowering diet and subsequent fluvastatin treatment (Lescol, Novartis; 20 mg/day) on serum lipids and lipoproteins was investigated in 21 diabetic patients (eight women, 13 men, age range 31-63 years, BMI 25.9 +/- 4.5 kg/m2) who had undergone successful kidney transplantation. A cholesterol-lowering diet followed for 8 weeks had apparently no effect on serum lipid concentrations. Fluvastatin applied afterwards for 12 months significantly decreased the total cholesterol, triglyceride and LDL cholesterol levels from 7.7 +/- 0.94, 2.84 +/- 0.85 and 4.87 +/- 1.05 mmol/l to 6.40 +/- 0.74, 2.64 +/- 0.86 and 3.52 +/- 0.69 mmol/l, P < 0.001, < 0.05 and < 0.001, respectively, while the level of HDL cholesterol increased from 1.12 +/- 0.28 to 1.52 +/- 0.39 mmol/l, P < 0.001. Serum concentration of lipoprotein(a) remained unchanged. The serum level of apolipoprotein-A1 increased from 1.52 +/- 0.28 to 1.83 +/- 0.29 mmol/l (P < 0.01) and that of lipoprotein-B decreased from 1.37 +/- 0.20 to 1.20 +/- 0.36 mmol/l (P < 0.05). These maximum changes were achieved by the 12th week of fluvastatin treatment, and no further significant change was observed in the remaining part of the year. The other parameters that could have influenced lipid metabolism (doses of diuretics and steroid, daily dose and serum level of cyclosporin, kidney function, degree of proteinuria, HbA1c, etc.) remained unchanged throughout the study. Thus, the improvement in lipid concentrations can be ascribed exclusively to fluvastatin. No side effects were observed during the 1-year follow up. Liver enzymes and CPK remained within the normal reference limits. Fluvastatin proved to be an effective and safe drug for treating the dyslipidaemia of transplanted patients receiving steroid cyclosporin immunosuppression.
在21例成功接受肾移植的糖尿病患者（8名女性，13名男性，年龄范围31 - 63岁，体重指数25.9±4.5kg/m²）中，研究了降胆固醇饮食及随后氟伐他汀治疗（来适可，诺华公司；20mg/天）对血脂和脂蛋白的影响。为期8周的降胆固醇饮食对血脂浓度显然没有影响。随后应用氟伐他汀12个月，总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平显著降低，分别从7.7±0.94、2.84±0.85和4.87±1.05mmol/L降至6.40±0.74、2.64±0.86和3.52±0.69mmol/L，P分别<0.001、<0.05和<0.001，而高密度脂蛋白胆固醇水平从1.12±0.28mmol/L升至1.52±0.39mmol/L，P<0.001。脂蛋白(a)的血清浓度保持不变。载脂蛋白-A1的血清水平从1.52±0.28mmol/L升至1.83±0.29mmol/L（P<0.01），而脂蛋白-B从1.37±0.20mmol/L降至1.20±0.36mmol/L（P<0.
